{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Lymphoma+%28FL%29&page=2", "query": { "condition": "Follicular Lymphoma (FL)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Follicular+Lymphoma+%28FL%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-21T23:33:31.604Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02603445", "title": "Study of Safety and Efficacy of BCL201 and Idelalisib in Patients With FL and MCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Lymphoma, Mantle Cell Lymphoma" ], "interventions": [ { "name": "BCL201", "type": "DRUG" }, { "name": "Idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2015-11-16", "completion_date": "2018-07-10", "has_results": false, "last_update_posted_date": "2020-02-24", "last_synced_at": "2026-05-21T23:33:31.604Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603445" }, { "nct_id": "NCT06792825", "title": "HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2025-08-07", "completion_date": "2031-07-08", "has_results": false, "last_update_posted_date": "2025-08-12", "last_synced_at": "2026-05-21T23:33:31.604Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06792825" }, { "nct_id": "NCT02611323", "title": "A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 133, "start_date": "2016-03-09", "completion_date": "2022-08-04", "has_results": true, "last_update_posted_date": "2023-10-10", "last_synced_at": "2026-05-21T23:33:31.604Z", "location_count": 10, "location_summary": "Tucson, Arizona • New Haven, Connecticut • Pembroke, Florida + 7 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Pembroke", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT02611323" }, { "nct_id": "NCT06014762", "title": "P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High-grade B-cell Lymphoma", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)", "Transformed Follicular Lymphoma (tFL)", "Follicular Lymphoma Grade 3B", "DLBCL", "DLBCL - Diffuse Large B Cell Lymphoma", "DLBCL Arising From Follicular Lymphoma", "DLBCL, Diffused Large B Cell Lymphoma", "DLBCL NOS" ], "interventions": [ { "name": "P-CD19CD20-ALLO1", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Poseida Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-04-16", "completion_date": "2041-03", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-05-21T23:33:31.604Z", "location_count": 16, "location_summary": "Loma Linda, California • Los Angeles, California • Orlando, Florida + 13 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT06014762" }, { "nct_id": "NCT06112847", "title": "Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Epcoritamab", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2024-01-24", "completion_date": "2026-07-17", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-21T23:33:31.604Z", "location_count": 2, "location_summary": "Duarte, California • Irvine, California", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06112847" }, { "nct_id": "NCT06542250", "title": "A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Malignancies" ], "interventions": [ { "name": "AZD5492", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 174, "start_date": "2024-09-18", "completion_date": "2028-02-14", "has_results": false, "last_update_posted_date": "2026-05-01", "last_synced_at": "2026-05-21T23:33:31.604Z", "location_count": 10, "location_summary": "La Jolla, California • Boston, Massachusetts • Rochester, Minnesota + 6 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06542250" }, { "nct_id": "NCT07154823", "title": "A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Acute Myeloid Leukaemia (AML)", "Follicular Lymphoma ( FL)" ], "interventions": [ { "name": "None - Observational Study", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Tempus AI", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": null, "sex": "ALL", "summary": "0 Years and older" }, "enrollment_count": 550, "start_date": "2026-01-27", "completion_date": "2035-11", "has_results": false, "last_update_posted_date": "2026-03-03", "last_synced_at": "2026-05-21T23:33:31.604Z", "location_count": 5, "location_summary": "Bethesda, Maryland • Reno, Nevada • Maumee, Ohio + 2 more", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Reno", "state": "Nevada" }, { "city": "Maumee", "state": "Ohio" }, { "city": "York", "state": "Pennsylvania" }, { "city": "Sioux Falls", "state": "South Dakota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07154823" }, { "nct_id": "NCT03571828", "title": "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B-cell Lymphoma(DLBCL)", "Mantle Cell Lymphoma (MCL)", "Follicular Lymphoma (FL)" ], "interventions": [ { "name": "AMG 562", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 10, "start_date": "2018-10-29", "completion_date": "2022-01-12", "has_results": true, "last_update_posted_date": "2024-03-22", "last_synced_at": "2026-05-21T23:33:31.604Z", "location_count": 7, "location_summary": "Duarte, California • Los Angeles, California • Baltimore, Maryland + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03571828" }, { "nct_id": "NCT02624986", "title": "A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) Participants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Idasanutlin", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2015-12-23", "completion_date": "2019-05-20", "has_results": true, "last_update_posted_date": "2020-05-18", "last_synced_at": "2026-05-21T23:33:31.604Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Aurora, Colorado • Louisville, Kentucky + 5 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Cary", "state": "North Carolina" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT02624986" }, { "nct_id": "NCT02362035", "title": "ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Follicular Lymphoma (FL)", "CLL", "Small Lymphocytic Lymphoma (SLL)", "Richter's Syndrome", "Mantle Cell Lymphoma (MCL)", "Indolent Non Hodgkin Lymphoma", "Waldenström Macroglobulinemia", "Multiple Myeloma", "Hodgkin Lymphoma", "Burkitt Lymphoma", "Marginal Zone Lymphomas", "Mediastinal Large B Cell Lymphoma", "Hairy Cell Leukemia" ], "interventions": [ { "name": "Acalabrutinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acerta Pharma BV", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 161, "start_date": "2015-02-20", "completion_date": "2025-10-27", "has_results": true, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-05-21T23:33:31.604Z", "location_count": 19, "location_summary": "Tucson, Arizona • Los Angeles, California • Denver, Colorado + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Niles", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02362035" } ] }